PRECIGEN, INC. Operating Leases, Future Minimum Payments, Remainder of Fiscal Year
PRECIGEN, INC. (PGEN) had Operating Leases, Future Minimum Payments, Remainder of Fiscal Year of $1.51 million as of 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Notes › Leases
us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear · last filed 2018-11-08
- 2018-09-30: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $1.51M.
- 2018-06-30: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $3.69M.
- 2018-03-31: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $6.10M.
- 2017-09-30: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $1.25M.
| Period end | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year |
|---|---|
| 2018-09-30 | $1.51M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $3.69M 10-Q · filed 2018-08-13 |
| 2018-03-31 | $6.10M 10-Q/A · filed 2018-08-13 |
| 2017-09-30 | $1.25M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $3.16M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $3.90M 10-Q · filed 2017-05-10 |
| 2016-09-30 | $705.00K 10-Q · filed 2016-11-09 |
| 2016-06-30 | $1.97M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $2.46M 10-Q · filed 2016-05-10 |
| 2015-09-30 | $739.00K 10-Q · filed 2015-11-09 |
| 2015-06-30 | $1.66M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $2.91M 10-Q · filed 2015-05-11 |
| 2014-09-30 | $981.00K 10-Q · filed 2014-11-13 |
| 2014-06-30 | $1.92M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $3.14M 10-Q · filed 2014-05-09 |
| 2013-09-30 | $784.00K 10-Q · filed 2013-11-07 |
| 2013-06-30 | $1.42M 10-Q/A · filed 2013-10-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |